Remote Interactive Evaluations News Today

Falls Church, VA (PRWEB) February 27, 2023 -- Grace McNally, senior vice president of regulatory compliance at Greenleaf Health, and a 33-year veteran of the

With President Biden’s signature, the Food and Drug Omnibus Reform Act of 2022 (FDORA), part of the larger Consolidated Appropriations Act of...

We increasingly encounter research and Development collaboration partners relying On various research tools, cell lines, and other Technologies to…

Press release content from Business Wire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation.

Key Takeaways - The COVID-19 pandemic led the U.S. Food and Drug Administration (FDA) to pause most foreign and domestic inspections and begin conducting remote interactive...

More than a year into the COVID-19 pandemic and FDA’s abrupt suspension of on-site inspections in March 2020, the agency released the...

The US agency continues to keep a watchful eye over the nation’s pandemic response, issuing advice to professionals and taking action where appropriate. According to NPR​, as of this week, 246m doses of the various vaccines against COVID-19 have been distributed in the US. More than 105m Americans have been fully vaccinated, or nearly 32% of the total population. However, the pandemic is far from over, and US Food and Drug Administration (FDA) measures to monitor...

FDA Issues Pandemic Remote Inspection Guidance For Drug Manufacturing Facilities By Mark Durivage, Quality Systems Compliance LLC On April 14, 2021, the FDA released a new guidance, Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency, to address the coronavirus disease 2019 (COVID-19) public health emergency. This guidance was implemented without prior public comment because the FDA determined that prior public ...

Federal Register notice finally announcing the fee rates under the Over-the-Counter (OTC) Monograph Drug User Fee Program for Fiscal Year 2021. As we discussed in a previous Bulletin, the CARES Act, among other things, amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to allow FDA to assess and collect user fees from qualifying owners of OTC monograph drug facilities and qualifying submitters of OTC monograph order requests (OMORs). The fees are meant to support FDA in its OTC monogra...